{
  "id": "fdc629b622eb788c",
  "title": "Perioperative Enfortumab Vedotin / Pembrolizumab Meets EFS , OS , pCR End Points in Cisplatin - Eligible MIBC",
  "description": "20251217T204500Z",
  "content": "",
  "source": "onclive.com",
  "source_url": "https://www.onclive.com/view/perioperative-enfortumab-vedotin-pembrolizumab-meets-efs-os-pcr-end-points-in-cisplatin-eligible-mibc",
  "published_at": "20251217T204500Z",
  "fetched_at": "2025-12-18T00:22:47.263985+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.onclive.com/view/perioperative-enfortumab-vedotin-pembrolizumab-meets-efs-os-pcr-end-points-in-cisplatin-eligible-mibc",
    "url_mobile": "",
    "title": "Perioperative Enfortumab Vedotin / Pembrolizumab Meets EFS , OS , pCR End Points in Cisplatin - Eligible MIBC",
    "seendate": "20251217T204500Z",
    "socialimage": "https://cdn.sanity.io/images/0vv8moc6/onclive/9ad6b044f4ff5a3fa24ccbec5942b5a02b126c9f-1280x720.jpg",
    "domain": "onclive.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}